Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Post by Sarb99on Apr 24, 2021 7:18pm
389 Views
Post# 33062345

All these upcoming updates should add more revenue.

All these upcoming updates should add more revenue.

Most of these streams should add extra revenue immediately. All these prices are in the USD and converting into Canadian is even better revenue. All this potential revenue is on top of whatever collection sites already generating. Once they publish Blowfish clinical trials results, they can submit them to FDA for EUA ahead of many. All these extra services adding extra revenue without paying extra expenses. Same staff can perform these services. 

 

For example, a vaccine contract is $40 per shot https://www.cms.gov/medicare/covid-19/medicare-covid-19-vaccine-shot-payment. Then as Doug said there is an ongoing discussion to sell Nuturell spray. 

 

Govt-funded PCR testing pays $75-$100 per test. The HRSA COVID-19 Uninsured Program plans to continue to reimburse independent laboratories at a rate of $100 for COVID-19 PCR testing claims with HCPCS codes U0003 and U0004 and will not implement the add-on reimbursement for HCPCS U0005 in January 2021. 

 

Home-based covid testing kits retail at the affordable price of $19.99. Collection Sites’ expert lab processing and testing fee of $89.99 can be covered by health insurance or credit card. HRSA eligible testers receive lab processing and testing for free. So $109.98 per testing kit.

 

  1. According to the webinar, we should see the Blowfish clinical trials result published in the next week or two. 
  2. Vaccine contract should be long-term revenue-generating as people need a booster shot every 6-12 months https://www.biospace.com/article/pfizer-ceo-another-covid-19-vaccine-will-likely-be-needed-in-12-months/ 
  3. Home-based covid testing kits should add extra revenue. Medivolve is working with  https://www.mcdadeassociates.com/ to put it in the big box stores and online to sell. Test Kits from Collection Sites to be sold in convenience stores and big-box retailers across the United States, expanding on its mission to bring convenient, fast and reliable COVID-19 testing to more homes, schools and businesses. https://ca.finance.yahoo.com/news/collection-sites-makes-affordable-fda-113000955.html
  4. HRSA Govt-funded covid testing is a good addition to add uninsured and undocumented clients. "No cost" tests are already added to the website as coming soon. https://www.hhs.gov/sites/default/files/uninsured-patient-covid-services-poster.pdf
  5. As an AditxtScore™ Channel Partner, Collection Sites, LLC will now offer its customers AditxtScore™ for COVID-19 as an immune monitoring service. This added service should add some extra revenue
  6. Nuturell disinfecting spray can bring add-on Revenue.
  7. The first quarter financials should show $17 million-plus revenue according to the officially released numbers. 
  8. Telehealth Projects is to assure investors of the long-term plan. According to Doug Sommerville in the webinar first delivery of the pieces of equipment is expected next week. 
  9. Here is the Webinar video https://www.youtube.com/watch?v=EFmEZjxl8q8
<< Previous
Bullboard Posts
Next >>